IP Verse

Nicotinamide Mononucleotide Derivatives And Use Thereof In The Treatment And Prevention Of A Red Blood Cell Disorder

Patent No. EP4196127 (titled "Nicotinamide Mononucleotide Derivatives And Use Thereof In The Treatment And Prevention Of A Red Blood Cell Disorder") was filed by Nuvamid on Dec 17, 2021. The application was issued on Jan 31, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SCHLICHMay 30, 2024SCHLICH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4196127

NUVAMID
Application Number
EP21839533A
Filing Date
Dec 17, 2021
Status
Granted And Under Opposition
Dec 29, 2023
Publication Date
Jan 31, 2024
External Links
Slate, Register , Google Patents